Howard Wold

Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a Day 1 and Day 8 High-Dose Regimen

David R. Gandara, Howard Wold, Edith A. Perez et al. · JNCI Journal of the National Cancer Institute · 1989 · 69 citations

Medicine, Oncology, Pharmacology +16

Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide

Roy A. Lysaa, Trude Giverhaug, Howard Wold et al. · European Journal of Clinical Pharmacology · 1996 · 63 citations

Medicine, Biochemistry, Pharmacology +7

High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.

David R. Gandara, Michael W. DeGregorio, Howard Wold et al. · Journal of Clinical Oncology · 1986 · 61 citations

Pharmacy, Oncology, Pharmacology +17

Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening

Rachel Hae‐Soo Joung, Timothy W. Mullett, Scott H. Kurtzman et al. · JAMA Network Open · 2022 · 28 citations · Full text

Public Health, Oncology, Public Health Practice +14

High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group

David R. Gandara, Edith A. Perez, Howard Wold et al. · Cancer Chemotherapy and Pharmacology · 1990 · 14 citations

Medicine, Oncology, Cancer Pharmacology +16